|Basic InformationLookupsLatest News|Ketamine Beneficial for Certain Patients With Mood DisordersPatients Reluctant to Comply With Drug-Only Psychiatric TreatmentPatients Often Reject Drug-Only Psychiatric TreatmentStudy Links Psychiatric Disorders to Stroke RiskAnxiety, Depression May Up Mortality Risk for Some CancersMental Health May Affect Chances Against CancerObamacare Covered More People With Mental Illness, AddictionsMany With Mental Illness Miss Out on HIV TestsPlastic Surgeons Often Miss Patients' Mental DisordersMortality Risk in T2DM Increased With Depression and/or AnxietyMost Smokers With Mental Illness Want to Kick the HabitRate of Psychiatric Drug Use About 16 Percent in U.S. Adults1 in 6 U.S. Adults Takes a Psychiatric Drug: StudyFor People With Mental Health Woes, Pets Can Be InvaluableHealth Tip: Thinking About Psychological Therapy?Heart Rate, BP in Male Teens Tied to Later Risk for Psych DisordersU.S. Psychiatric Patients Face Long Waits in ERsAre Some Blood Pressure Meds Linked to Depression, Bipolar Risk?Study Links Pot Use to Relapse in Psychosis PatientsInternet Addiction May Be Red Flag for Other Mental Health Issues: StudyPsychiatric Patients Face Longer Waits in ERParents' Psychiatric Issues May Adversely Affect Some ChildrenAntipsychotic Meds Pose Little Danger to Fetus, Study FindsInfertility Patients' Mental Health Problems Often UnaddressedStudy of Teen Brains Offers Clues to Timing of Mental IllnessHealth Tip: Take Steps to Stay Mentally HealthyAre 'Workaholics' Prone to OCD, Anxiety?Mentally Ill Still Gain Illegal Possession of Guns, Study ShowsMental Disorders Were Most Costly in U.S. in 2013For New Antipsychotic Users, Dose, Duration Impact MortalityNo Link Between Anti-Smoking Drugs, Mental Health Issues: StudyU.S. Soldier in Custody Following Slaying of 5 Americans in IraqQuestions and AnswersLinksBook Reviews
For New Antipsychotic Users, Dose, Duration Impact Mortality
Updated: May 17th 2016
TUESDAY, May 17, 2016 (HealthDay News) -- Dose and duration of therapy are associated with mortality for new antipsychotic users, according to a study published online May 10 in the Journal of the American Geriatrics Society.
Linda Simoni-Wastila, Ph.D., from the University of Maryland in Baltimore, and colleagues conducted a retrospective cohort study of Medicare beneficiaries who had a Minimum Data Set 2.0 clinical assessment completed between 2007 and 2009. The authors identified three mutually exclusive cohorts of new antipsychotic users with evidence of severe mental illness (SMI; 5,621 participants); dementia with behavioral symptoms (dementia + behavior) without SMI (1,090 participants); or delirium without SMI or dementia + behavior (2,100 participants). The dose (modified standardized daily dose [mSDD]) and duration of therapy with antipsychotic were assessed monthly.
The researchers found that mortality risk was significantly lower for new antipsychotic users with a mSDD of ≤1 versus those with a mSDD >1 (hazard ratio [HR]SMI, 0.77; HRdementia + behavior, 0.52; and HRdelirium, 0.61, respectively). Significantly lower mortality was seen with longer duration of antipsychotic use (91 to 184 days for SMI and delirium) versus short duration of use (≤30 days for SMI; ≤7 days for delirium). In the SMI cohort, the interaction between dose and duration was statistically significant (P < 0.001).
"Prescribers should monitor antipsychotic dosage throughout the course of antipsychotic treatment and customize dose and duration regimens to an individual's indications," the authors write.
Full Text (subscription or payment may be required)
This article: Copyright © 2016 HealthDay. All rights reserved.